Tirzepatide vs Retatrutide

Tirzepatide and retatrutide represent two steps in the same line of peptide design: building more than one hormone signal into a single molecule. Tirzepatide combines GIP receptor and GLP-1 receptor agonism. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist.

The two also sit at very different points in development. Tirzepatide is an FDA-approved medicine with a large published literature, while retatrutide is investigational and still moving through late-stage clinical trials. For researchers, that means tirzepatide offers a well-characterized dual-agonist reference, while retatrutide opens questions about what glucagon receptor activity contributes when it is combined with incretin signaling, particularly around energy expenditure and liver metabolism. This comparison lays out their mechanisms, structure, research status and laboratory handling side by side. PRIME supplies both as lyophilized powder for laboratory research use only.

Tirzepatide: the approved dual agonist

Tirzepatide is a 39-amino-acid synthetic peptide built largely on the sequence of glucose-dependent insulinotropic polypeptide (GIP). It activates both the GIP receptor and the GLP-1 receptor, and a fatty diacid side chain supports albumin binding for a long duration of action. It was the first dual GIP/GLP-1 receptor agonist to reach approval, and it is marketed in the US as Mounjaro and Zepbound.

In research, tirzepatide is valuable because it is so well characterized. Areas that have been investigated include:

• Glucose regulation and insulin sensitivity
• Body-weight and fat-mass regulation
• Lipid metabolism and adipose tissue biology
• How signaling at the GIP and GLP-1 receptors differs from the native hormones

In a comparison with retatrutide, tirzepatide usually plays the role of the dual-agonist reference. Because both molecules share GIP and GLP-1 receptor activity, differences observed between them in a given model can help researchers reason about the contribution of the glucagon receptor, keeping in mind that the molecules also differ in structure and relative potency at each receptor.

PRIME supplies tirzepatide (GLP-2 TZ) as a lyophilized powder for in-vitro and preclinical research. It is sold for laboratory research use only and is not for human consumption.

Retatrutide: the investigational triple agonist

Retatrutide is a single synthetic peptide engineered to activate three receptors: the GIP receptor, the GLP-1 receptor and the glucagon receptor. Like the other long-acting incretin peptides, it carries a fatty acid modification that extends its duration of action.

Adding glucagon receptor activity is the defining feature. Glucagon is usually thought of as a hormone that raises blood glucose, but it also acts on the liver and on energy expenditure. The design idea behind a triple agonist is that the incretin components can balance the glucose-raising effect of glucagon while the glucagon component contributes its other metabolic actions. Research areas that have been investigated include:

• Body-weight regulation
• Glucose regulation in models of type 2 diabetes
• Energy expenditure and substrate use
• Liver fat and hepatic metabolism

Retatrutide is investigational. It has been studied in clinical trials, with late-stage trials under way, but it is not an FDA-approved medicine. Much of what is known still comes from ongoing research, so findings should be read as provisional.

PRIME supplies retatrutide (GLP-3 RT) as a lyophilized powder for in-vitro and preclinical research. It is sold for laboratory research use only and is not for human consumption.

The choice depends on whether glucagon receptor signaling is part of your research question.

Tirzepatide fits studies that need a well-characterized dual incretin agonist: work on GIP and GLP-1 receptor interaction, studies that benefit from a large published literature to compare against, or designs that need an approved-drug reference arm.

Retatrutide fits studies focused on what glucagon receptor agonism adds: energy expenditure, hepatic fat and liver metabolism, or how a triple agonist behaves relative to dual and single agonists in the same model. Because it is investigational, it is best suited to exploratory work where results are interpreted alongside the emerging literature.

Many metabolic study designs run the incretin peptides as a series, from single to dual to triple agonist. The semaglutide vs retatrutide comparison covers the single-to-triple step. For full background, read the tirzepatide research guide and the retatrutide research guide. Every batch has a published certificate of analysis on the lab results page.

For laboratory research use only. Not for human consumption.